Despite the low frequency of IDH1 mutation in human cancer, further analysis revealed significant to extremely significant co-occurrence of IDH1 and TP53 alterations but mutual exclusivity between IDH2 and TP53 alterations in all three datasets (Table 2 and Table S2). This evidence concerns the gene IDH2 and cancer.